RAIR Thyroid Cancer Research
Temporada 1
por John Londt
Here are the direct links to the February 2026 research and trials: https://pubmed.ncbi.nlm.nih.gov/41686811/ https://pubmed.ncbi.nlm.nih.gov/41708943 https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1720670/full https://pmc.ncbi.nlm.nih.gov/articles/PMC12876518/ https://pmc.ncbi.nlm.nih.gov/articles/PMC12921828/ https://clinicaltrials.gov/study/NCT07419932 https://clinicaltrials.gov/study/NCT07436455
Definitive Radiotherapy for Oligometastatic and Oligoprogressive Thyroid Cancer: A Potential Strategy for Systemic Therapy Deferral (2024) Stereotactic Body Radiotherapy for Extracranial Oligometastatic Disease from Head and Neck Primary Cancers: A Systematic Review and Meta-Analysis The Role of Stereotactic Radiotherapy in Deferring the Need for Systemic Therapies in Patients with Progressive Oligometastatic Iodine-Refractory Thyroid Cancer Oligometastatic disease from differentiated thyroid cancer: best treatment schemes Stereotactic Radiotherapy for Oligometastatic Head and Neck Cancers NotebookLM
Advances in Immunotherapy for Thyroid Malignancies: https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1754058/full "Living Sentinel" Implant for Continuous Thyroid Monitoring: https://www.cmu.edu/news/stories/archives/2026/january/inside-cmus-push-to-transform-treatment-for-cancer-organ-failure-and-chronic-disease Fatty Acid Metabolism Drives Bone Metastasis: https://www.mdanderson.org/cancerwise/new-research-advances-in-our-understanding-of-cancer-metabolism.h00-159852189.html Cryoablation of Bone Metastases in Thyroid Cancer: https://pubmed.ncbi.nlm.nih.gov/41543023/ Sugary Drinks Reprogram Metabolism to Drive Metastasis: https://www.mdanderson.org/cancerwise/new-research-advances-in-our-understanding-of-cancer-metabolism.h00-159852189.html AI in Screening Cuts Interval Cancer Rates by 12%: https://www.theguardian.com/science/2026/jan/29/ai-use-in-breast-cancer-screening-cuts-rate-of-later-diagnosis-by-12-study-finds First Immunotherapy (Retifanlimab) Recommended for Advanced Anal Cancer: https://www.ema.europa.eu/en/news/first-immunotherapy-based-treatment-recommended-advanced-anal-cancer Circulating Tumor DNA (ctDNA) in Germ Cell Tumors: https://ascopubs.org/journal/jco Pancreatic Cancer’s "Sugar Cloak" Decoded: https://news.northwestern.edu/ Nuvalent "OnTarget 2026" Plan for RET Inhibitors: https://investors.nuvalent.com/
* Study identifies patients who would benefit from redifferentiation therapy for thyroid cancer https://www.mayoclinic.org/medical-professionals/endocrinology/news/study-identifies-patients-who-would-benefit-from-redifferentiation-therapy-for-thyroid-cancer/mac-20592451 * BRAF and MEK Inhibition Beyond Dabrafenib-Trametinib in Advanced Thyroid Cancer https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2026.1694805/full * Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers https://pubmed.ncbi.nlm.nih.gov/37917101/ * Off-Label Treatment Offers Hope for Patients With Rare Medullary Thyroid Cancer https://advances.massgeneral.org/oncology/article.aspx?id=1608 * Redifferentiation Effect of Larotrectinib for NTRK Fusion-Positive Pediatric Thyroid Cancer https://pmc.ncbi.nlm.nih.gov/articles/PMC12209784/ * Pilot Study of BRAF or MEK Inhibition to Restore Iodine Uptake (NCT04554680) https://clinicaltrials.gov/study/NCT04554680 * Lutathera (177Lu-DOTATATE) Orphans: State of the Art and Future Application of Radioligand Therapy https://www.researchgate.net/publication/369730901_Lutathera_Orphans_State_of_the_Art_and_Future_Application_of_Radioligand_Therapy_with_Lu-DOTATATE * Identification of new small molecules for selective inhibition of SERCA 1 in patient-derived metastatic papillary thyroid cancer https://www.researchgate.net/publication/388836405_Identification_of_new_small_molecules_for_selective_inhibition_of_SERCA_1_in_patient-derived_metastatic_papillary_thyroid_cancer * Clinical Indications for Treatment with Multi-Kinase Inhibitors in Patients with RR-DTC https://www.mdpi.com/2072-6694/13/9/2279 * A TIMELESS link to dedifferentiation in thyroid cancer https://joe.bioscientifica.com/downloadpdf/view/journals/joe/267/1/JOE-25-0136.pdf